Global experts to compare evolving prostate cancer guidelines at AUA Plenary panel
Updates are expected to show more convergence than conflict.
Leading urology experts from across the United States and Europe will dissect and compare the latest advancements in prostate cancer care, highlighting growing alignment between international treatment guidelines.
The session, AUA-EAU Guidelines Panel Discussion: A Case-Based Comparison of the Advanced Prostate Cancer Guidelines, will focus on recent updates to both the European Association of Urology (EAU) guidelines and the forthcoming American Urological Association (AUA) Advanced Prostate Cancer Amendment.
“The session reflects an increasing emphasis on collaboration across geographic boundaries in a rapidly evolving field,” said Kristen R. Scarpato, MD, MPH, associate professor of urology at Vanderbilt University Medical Center in Nashville, Tennessee. “The partnership between EAU and AUA leading experts has provided a platform for comparing approaches and identifying areas of consensus in prostate cancer management.”
Aligning global perspectives
Despite differences in health care systems and clinical practices, the updated guidelines are expected to show more convergence than conflict, signaling a stronger global consensus on how best to treat advanced disease.
Focus on personalized, complex care
Among the key discussion points will be the expanding complexity of treating advanced prostate cancer, a field that has seen significant therapeutic and diagnostic innovation in recent years.
Highlights include:
- Management of biochemical recurrence following local therapy
- Treatment of metastatic castration-resistant prostate cancer (mCRPC)
- Integration of advanced diagnostic tools
- The shift toward personalized treatment strategies
As treatment options multiply, clinicians face increasingly nuanced decisions regarding therapy selection, sequencing and patient-specific considerations.
Case-based approach for real-world application
To bridge the gap between guidelines and clinical practice, the session will use a case-based format, allowing experts to walk through real-world scenarios and demonstrate how recommendations are applied in day-to-day patient care.
This approach aims to provide clinicians with practical takeaways on navigating subtle differences between guidelines while maintaining consistent standards of care.
Distinguished international panel
The plenary panel will feature a several internationally recognized leaders in urologic oncology:
- Kristen R. Scarpato, MD, MPH, Vanderbilt University, Nashville, Tennessee
- Derya Tilki, MD, Martini-Klinik Prostate Cancer Center/Koc University Hospital, Istanbul, Turkey
- Alice Yu, MD, Moffitt Cancer Center, Tampa, Florida
- Giorgio Gandaglia, MD, San Raffaele Hospital, Milan, Italy
- Chad Ritch, MD, Cleveland Clinic, Weston, Florida
Advancing standards in a rapidly changing field
As prostate cancer care continues to evolve, the session underscores the importance of harmonizing global guidelines while incorporating emerging evidence and innovations.
By highlighting both shared principles and key differences, the panel aims to equip clinicians with the necessary knowledge to deliver evidence-based, patient-centered care in an increasingly complex treatment landscape.
